Marvin T Nieman, Eileen Pagan-Ramos, Mark Warnock, Yelena Krijanovski, Ahmed A K Hasan, Alvin H Schmaier
Index: FEBS Lett. 579(1) , 25-9, (2005)
Full Text: HTML
The angiotensin converting enzyme breakdown product of bradykinin, bradykinin 1-5 (RPPGF), inhibits thrombin-induced human or mouse platelet aggregation. RPPGF binds to the exodomain of human protease-activated receptor 1 (PAR1). Studies determined if RPPGF also binds to the exodomain of human PAR4. RPPGF binds to a peptide of the thrombin cleavage site on PAR4. Recombinant wild-type and mutated exodomain of human PAR4 was prepared. The N-terminal arginine on RPPGF binds to the P2 position or proline46 on PAR4 to block thrombin cleavage. These data indicate that RPPGF influences thrombin activity by binding to the thrombin cleavage site on both PAR4 and PAR1.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Bradykinin Fragment 1-5
CAS:23815-89-6 |
C27H40N8O6 |
|
Angiotensin-converting enzyme inhibition and smoking potenti...
2004-10-01 [Clin. Pharmacol. Ther. 76(4) , 379-87, (2004)] |
|
Thrombostatin inhibits cyclic flow variations in stenosed ca...
2001-11-01 [Thromb. Haemost. 86(5) , 1296-304, (2001)] |
|
Thrombostatin FM compounds: direct thrombin inhibitors - mec...
2008-05-01 [J. Thromb. Haemost. 6(5) , 837-45, (2008)] |
|
Bradykinin metabolism in rat hind limbs.
1998-08-01 [Shock 10(2) , 146-52, (1998)] |
|
Oral thrombostatin FM19 inhibits prostate cancer.
2010-11-01 [Thromb. Haemost. 104(5) , 1044-8, (2010)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
